Healthcare scales 85%, but margin pressure and execution risk limit near-term

Delivered ₹142 Cr; calculation shows exactly 84.6% growth from ₹77 Cr

Delivered ₹116 Cr; exactly -23.2% YoY from ₹151 Cr

Delivered OPM 29.6%; essentially corroborated within rounding

Delivered NPM exactly 17.1%; matches precisely

Confirmed in Q&A; on track for 36M FY27 guidance (4x quarterly production required)

Now 51% of revenue (₹142 Cr) vs 31% prior year; 85% YoY growth on Semaglutide scaling and regulatory approvals in Canada, Brazil.

On-track with 9M in Q1 tracking 36M FY target (4x quarterly). Second line pre-ramping at supplier; first line speed increase in progress.

Revised to flat FY27 vs FY26 (was expected to grow). Revenue down 24% YoY on soft Europe/US home furnishings demand.

Gross margin compressed near-term by commodity/freight inflation; EBITDA/PAT still expanded YoY but normalization delayed to Q3.

~9M total; 50-60% GLP-1, rest insulin + other molecules

Speed increased 9%; needs equipment by end Q2 for 30% further jump. Second line pre-ramped to 80%+ at supplier before shipment.

Evolving situation; customer partners have supply chain issues. Should be able to go beyond 36M.

Commodity/freight inflation post-March, premium airlifts needed, customer pass-through delayed. Expect normalization Q3.

Don't name customer; multiple pharma partners, approvals in various markets. Gap in market needs filling; remain confident.

~50-55% commitments/indications; rest being worked. Commercial sales by end FY28 for Europe FY28+ and future global markets 2030-31.

24-30 months (not guidance; projection). Building portfolio by adding products to customer wins.

Reusable: advanced, testing now, CPHI Milan showcase. Emergency: 18 months in, closure end 2027, 99.999% reliability needed, auto-injection feature. On-body: partnership-driven, 3-15ml range. Costs $6-10 (emergency), $15-35 (on-body); low-to-mid millions scale.

Above average, good feedback. Statistically strong performance; no batch release decline observed. Very less issues on device side.

Very generic question; refer to research reports for market size details.

9M in Q1 tracking to 36M (4x quarterly production needed). Company signals confidence to beat if customer supply chain stabilizes. No INR revenue target given.

Commodity/freight inflation post-March causing near-term pressure; pass-through with customers progressing. EBITDA/PAT expected to continue YoY expansion.

Semicon targeting initial market needs; full capex phased as customers scale. Consumer Elec facility to be set up once market clarity improves.

Large pharmaceutical customer (implied Dr. Reddy's, ₹423 Cr order base referenced in earlier press release) facing impurities in Canada, technical issues in Brazil. Company cannot confirm customer or current status. Healthcare segment (51% of revenue) dependent on pharma partners' successful commercial execution.

Second 25M-pen capacity line operating at only 109% of planned speed. Needs additional equipment by end Q2 for planned 30% jump to reach target efficiency. Delays could constrain 36M FY guidance if not resolved.

Gross margin compressed by polymer/commodity inflation and elevated freight costs following March geopolitical tensions. Customer price pass-through delayed; near-term headwind expected through Q2, recovery target Q3. Impacts profitability despite volume growth.

Consumer segment (home furnishings, appliances) down 24% YoY on soft Europe/US demand. Management revised FY27 guidance to flat vs FY26, abandoning growth expectations. Long-term headwind unless macro improves.

Chinese manufacturers pricing GLP-1 devices at $1.50-1.70 vs Shaily's $2+ per device. Described as copycat 20-year-old technology, some products infringing patents. Pricing threat lower than feared, but potential market share loss.